Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. (1st June 2019) - Conti, A.; Peccerillo, F.; Amerio, P.; Balato, A.; Bardazzi, F.; Bianchi, L.; Burlando, M.; Cannavò, S.P.; Chiricozzi, A.; Dapavo, P.; De Simone, C.; Fargnoli, M.C.; et al.